NCT00695032|Suspended
Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors
Biologic Evaluation of Renal Toxicity of Cisplatin and Ifosfamide (TOXIPLAT)
Loading search results
Biologic Evaluation of Renal Toxicity of Cisplatin and Ifosfamide (TOXIPLAT)
Sponsor study identifier
Secondary identifiers
interventional
80
1 country
1
Study Start
October 2007
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2012
Actual (reported)Study Completion
Not reported
Date not reportedRATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is evaluating kidney damage in patients receiving cisplatin and ifosfamide for solid tumors.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 2007
Date type not reportedThis date has not been verified as actual or estimated.
June 7, 2008
Actual (reported)June 11, 2008
Actual (reported)September 2012
Actual (reported)Evolution of different biomarkers
Sensitivity, specificity, and predictive value (positive and negative) of different markers
Institut Claudius Regaud
Toulouse, 31052, France
Christine Chevreau-Dalbianco, MD
Institut Claudius Regaud
First Submitted
June 7, 2008
First Posted
June 11, 2008
Study Start
October 2007
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2012
Actual (reported)Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)
Natural Killer Cells in Older Patients With Acute Myeloid Leukemia
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Last Updated
November 5, 2014
Record last verified: 2014-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: